We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · August 24, 2022

Minimal Residual Disease–Driven Treatment Intensification With Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory CLL

Blood

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL
Blood 2022 Aug 03;[EPub Ahead of Print], L Scarfo, S Heltai, E Albi, E Scarano, L Schiattone, L Farina, R Moia, M Deodato, A Ferrario, M Motta, G Reda, R Sancetta, M Coscia, P Rivela, L Laurenti, M Varettoni, E Perotta, A Capasso, P Ranghetti, M Colia, P Ghia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading